FDA approves darolutamide for patients with non-metastatic castration-resistant prostate cancer
The US drug agency (FDA) has approved darolutamide, a non-steroidal androgen receptor antagonist, under the trade name of Nubeqa. The FDA-approved indication is the treatment … Read more